Healthy Subjects (HS)DPMPGNCT07921693
The Impact of Dietary Phosphorus on Postprandial Metabolic Responses and Markers of Metabolic Health
A study testing high carbohydrate meal with phosphorus supplementation and Full fat milk meal with phosphate binder in people with Healthy Subjects (HS) and Non Diabetic Patients, run by American University of Beirut Medical Center at 1 site in Lebanon.
Trial summary
To examine the effects of dietary phosphorus availability, including supplementation and restriction conditions, on postprandial glucose responses in healthy adults. Read more about this study
- Who is it for?
- Ages 18 to 64 yearsHealthy volunteers can take part
- Conditions the study is for
- Healthy Subjects (HS), Non Diabetic Patients, Normal Body Weight
- What is being tested?
- high carbohydrate meal with phosphorus supplementation and Full fat milk meal with phosphate binder
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 32 participants
- Where
- 1 siteLebanon
- Study dates
- 17 Feb 2023to 1 Apr 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 64 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Non diabetic
Who cannot join
- pregnancy or lactation
- diagnosis of diabetes
- recent weight loss (>3% within 3 months); psychiatric illness
Trial locations and contacts
1 site in 1 country.
About this study
Official title: The Effect of Dietary Phosphorus Manipulation on Postprandial Glycemia
To examine the effects of dietary phosphorus availability, including supplementation and restriction conditions, on postprandial glucose responses in healthy adults.
Read the detailed description
Two randomized, controlled, crossover experiments were conducted in healthy adults. Experiment 1 evaluated a refined carbohydrate test meal with phosphorus supplementation (~684 mg potassium phosphate) versus placebo. Experiment 2 assessed a dairy-based test meal under normal phosphorus availability versus reduced bioavailability using the phosphate-binding agent sevelamer carbonate. Each experiment followed a 10-day protocol comprising two intervention phases separated by a washout period. Within each phase, participants completed two identical test days per condition. Postprandial glucose was continuously monitored for 180 minutes. Primary outcomes included peak glucose, incremental glucose response (ΔBG), and incremental area under the curve (iAUC). Secondary outcomes included subjective appetite ratings assessed using validated visual analogue scale (VAS) questionnaires
- Being tested
- high carbohydrate meal with phosphorus supplementation, Full fat milk meal with phosphate binder
- Keywords
- phosphorus, phosphate binder, postprandial glucose, appetite score
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
high carbohydrate meal with phosphorus supplementationDietary supplement
high-carbohydrate meal with 684 mg of phosphorus supplement
Full fat milk meal with phosphate binderDrug
Full fat dairy milk meal with 800 mg sevelamer carbonate (Renvela®)
| Study group | Role | What they receive |
|---|---|---|
| refined low phosphorus carbohydrate meal | Sham comparator | High-carbohydrate meal with low phosphorus content Receives: Dietary Supplement: high carbohydrate meal with phosphorus supplementation |
| Full fat powdered milk meal | Active comparator | The meal or drink was composed of full-fat powdered milk meal which is naturally high in phosphorus Receives: Drug: Full fat milk meal with phosphate binder |
What is being measured
The primary outcome is the main question the study is designed to answer.
postprandial glucose
Monitoring glucose concentration
Measured: 10 days
Secondary outcomes (1)
Subjective appetite score
changes in appetite scores between 0 -10 points
Measured: 180 minutes
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Nov 2026
- Study start17 Feb 2023
- Primary completion1 Oct 2025
- Study completion1 Apr 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for Healthy Subjects (HS)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 32 participants (actual)
Sponsor and investigators
- Lead sponsor
- American University of Beirut Medical Center
- Sponsor type
- University, hospital or other
- Collaborators
- University of Nottingham
- Responsible party
- Principal investigator, Omar Obeid, American University of Beirut Medical Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07921693
- Sponsor's protocol ID
- BIO-2022-0015
- Other IDs
- BIO-2022-0015, FMHS 392-1121
- Acronym
- DPMPG
- Status last verified
- Nov 2026
- First submitted
- 24 Sep 2026
- Last updated
- 6 Nov 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Hammoud RU, Jabbour MN, Tawil AN, Ghattas H, Obeid OA. Phosphorus Supplementation Mitigated Food Intake and Growth of Rats Fed a Low-Protein Diet. Curr Dev Nutr. 2017 Jul 27;1(8):e000943. doi: 10.3945/cdn.117.000943. eCollection 2017 Aug.
PubMed 29955716Ragi ME, El Mallah C, Toufeili I, Obeid O. Concomitant lysine and phosphorus addition to a wheat gluten protein diet highly amplified growth measures of rats. Nutrition. 2019 Jul-Aug;63-64:69-74. doi: 10.1016/j.nut.2018.11.009. Epub 2018 Nov 30.
PubMed 30933728El Khoury R, El Solh N, Olabi A, Toufeili I, Hlais S, Obeid O. Macromineral enrichment of white bread reduces postprandial glycaemia without altering sensory properties: a crossover study. East Mediterr Health J. 2020 Nov 11;26(11):1388-1395. doi: 10.26719/2020.26.11.1388.
PubMed 33226107
Study at a glance
From the registry record, last updated by the sponsor on 6 Nov 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Effect of Dietary Phosphorus Manipulation on Postprandial Glycemia
- ClinicalTrials.gov ID
- NCT07921693
- Acronym / sponsor ID
- DPMPG / BIO-2022-0015
- Keywords
- phosphorus, phosphate binder, postprandial glucose, appetite score
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 32 participants (actual)
- Lead sponsor
- American University of Beirut Medical CenterUniversity, hospital or other
- Collaborators
- University of Nottingham
- Study start
- 17 Feb 2023 (actual)
- Primary completion
- 1 Oct 2025 (actual)
- Study completion
- 1 Apr 2026 (actual)
- First posted
- 6 Nov 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To examine the effects of dietary phosphorus availability, including supplementation and restriction conditions, on postprandial glucose responses in healthy adults.
Detailed description
Two randomized, controlled, crossover experiments were conducted in healthy adults. Experiment 1 evaluated a refined carbohydrate test meal with phosphorus supplementation (~684 mg potassium phosphate) versus placebo. Experiment 2 assessed a dairy-based test meal under normal phosphorus availability versus reduced bioavailability using the phosphate-binding agent sevelamer carbonate. Each experiment followed a 10-day protocol comprising two intervention phases separated by a washout period. Within each phase, participants completed two identical test days per condition. Postprandial glucose was continuously monitored for 180 minutes. Primary outcomes included peak glucose, incremental glucose response (ΔBG), and incremental area under the curve (iAUC). Secondary outcomes included subjective appetite ratings assessed using validated visual analogue scale (VAS) questionnaires
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Single blind (participant)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| refined low phosphorus carbohydrate meal | Sham comparator | Dietary Supplement: high carbohydrate meal with phosphorus supplementationHigh-carbohydrate meal with low phosphorus content |
| Full fat powdered milk meal | Active comparator | Drug: Full fat milk meal with phosphate binderThe meal or drink was composed of full-fat powdered milk meal which is naturally high in phosphorus |
Who may qualify
- Ages
- 18 to 64 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (1 listed)
- Non diabetic
Key exclusion criteria (3 listed)
- pregnancy or lactation
- diagnosis of diabetes
- recent weight loss (>3% within 3 months); psychiatric illness
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| high carbohydrate meal with phosphorus supplementationhigh-carbohydrate meal with 684 mg of phosphorus supplement | Dietary supplement | refined low phosphorus carbohydrate meal |
| Full fat milk meal with phosphate binderFull fat dairy milk meal with 800 mg sevelamer carbonate (Renvela®) | Drug | Full fat powdered milk meal |
Primary outcome
postprandial glucose
Time frame: 10 days
Monitoring glucose concentration
1 secondary outcome
Subjective appetite score
Time frame: 180 minutes
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Nov 2026.
- Background: PubMed 29955716Hammoud RU, Jabbour MN, Tawil AN, Ghattas H, Obeid OA. Phosphorus Supplementation Mitigated Food Intake and Growth of Rats Fed a Low-Protein Diet. Curr Dev Nutr. 2017 Jul 27;1(8):e000943. doi: 10.3945/cdn.117.000943. eCollection 2017 Aug.
- Background: PubMed 30933728Ragi ME, El Mallah C, Toufeili I, Obeid O. Concomitant lysine and phosphorus addition to a wheat gluten protein diet highly amplified growth measures of rats. Nutrition. 2019 Jul-Aug;63-64:69-74. doi: 10.1016/j.nut.2018.11.009. Epub 2018 Nov 30.
- Background: PubMed 33226107El Khoury R, El Solh N, Olabi A, Toufeili I, Hlais S, Obeid O. Macromineral enrichment of white bread reduces postprandial glycaemia without altering sensory properties: a crossover study. East Mediterr Health J. 2020 Nov 11;26(11):1388-1395. doi: 10.26719/2020.26.11.1388.
- Individual participant dataSharing planned: No
Related trials for Healthy Subjects (HS)
RecruitingPhase 1
Bioequivalence Study Between YHP2508B and YHR2602 in Healthy Subjects
Healthy Subjects (HS)
RecruitingPhase 1
Bioequivalence Study Between YHP2508A and YHR2601 in Healthy Subjects
Healthy Subjects (HS)
Not yet recruitingEarly Phase 1
Multi-organ Imaging of Microvascular and Metabolic Function
Healthy Subjects (HS), Cardiovascular Diseases (CVD)
Recruiting
Methodological Study of Exercise and Hypoxic Conditions in Healthy Subjects
Healthy Subjects (HS), Exercise
Recruiting
Reactive Balance Training in Augmented Reality for Older Adults
Healthy Subjects (HS)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing high carbohydrate meal with phosphorus supplementation and Full fat milk meal with phosphate binder in people with Healthy Subjects (HS) and Non Diabetic Patients, run by American University of Beirut Medical Center at 1 site in Lebanon.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 6 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Lebanon. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
postprandial glucose (time frame: 10 days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07921693, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Nov 2026.